GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Ibere Pharmaceuticals (NYSE:IBER.U) » Definitions » Retained Earnings

IBER.U (Ibere Pharmaceuticals) Retained Earnings : $-5.84 Mil (As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Ibere Pharmaceuticals Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Ibere Pharmaceuticals's retained earnings for the quarter that ended in Sep. 2022 was $-5.84 Mil.

Ibere Pharmaceuticals's quarterly retained earnings increased from Mar. 2022 ($-7.28 Mil) to Jun. 2022 ($-5.89 Mil) and increased from Jun. 2022 ($-5.89 Mil) to Sep. 2022 ($-5.84 Mil).

Ibere Pharmaceuticals's annual retained earnings increased from . 20 ($0.00 Mil) to Dec. 2020 ($-0.01 Mil) but then declined from Dec. 2020 ($-0.01 Mil) to Dec. 2021 ($-10.85 Mil).


Ibere Pharmaceuticals Retained Earnings Historical Data

The historical data trend for Ibere Pharmaceuticals's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ibere Pharmaceuticals Retained Earnings Chart

Ibere Pharmaceuticals Annual Data
Trend Dec20 Dec21
Retained Earnings
-0.01 -10.85

Ibere Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Retained Earnings Get a 7-Day Free Trial -11.18 -10.85 -7.28 -5.89 -5.84

Ibere Pharmaceuticals Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Ibere Pharmaceuticals  (NYSE:IBER.U) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Ibere Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
2005 Market Street, Suite 2030, Philadelphia, PA, USA, 19103
Ibere Pharmaceuticals is a blank check company.
Executives
Elaine V Jones director C/O TARGACEPT, INC., 200 EAST FIRST STREET, SUITE 300, WINSTON-SALEM NC 27101
Osagie O Imasogie director, 10 percent owner, officer: Chief Executive Officer
Calvin B. Johnson director 2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Zoltan Kerekes director, 10 percent owner, officer: Chief Operating Officer 2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Louis J. Vollmer director 2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Lisa M. Gray director, 10 percent owner, officer: Chief Financial Officer 2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Henrietta Ukwu director 2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Pipv Capital Llc 10 percent owner 2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103

Ibere Pharmaceuticals Headlines